Comparison of Early Versus Delayed Oral β Blockers in Acute Coronary Syndromes and Effect on Outcomes by Bugiardini, Raffaele et al.
See	discussions,	stats,	and	author	profiles	for	this	publication	at:	https://www.researchgate.net/publication/287490790
Comparison	of	Early-vs-Delayed	Oral	Beta-
Blockers	in	Acute	Coronary	Syndromes	and	Effect
on	Outcomes
Article		in		The	American	Journal	of	Cardiology	·	December	2015
DOI:	10.1016/j.amjcard.2015.11.059
CITATIONS
0
READS
369
16	authors,	including:
Marija	Vavlukis
Ss.	Cyril	and	Methodius	University
102	PUBLICATIONS			167	CITATIONS			
SEE	PROFILE
Paolo	E	Puddu
Sapienza	University	of	Rome
456	PUBLICATIONS			4,531	CITATIONS			
SEE	PROFILE
Davor	Milicic
University	of	Zagreb
206	PUBLICATIONS			1,051	CITATIONS			
SEE	PROFILE
Lina	Badimon
Spanish	National	Research	Council
716	PUBLICATIONS			22,299	CITATIONS			
SEE	PROFILE
All	content	following	this	page	was	uploaded	by	Marija	Vavlukis	on	20	December	2015.
The	user	has	requested	enhancement	of	the	downloaded	file.	All	in-text	references	underlined	in	blue	are	added	to	the	original	document
and	are	linked	to	publications	on	ResearchGate,	letting	you	access	and	read	them	immediately.
 1 
Comparison of Early-vs-Delayed Oral Beta-Blockers in Acute 
Coronary Syndromes and Effect on Outcomes 
Brief title: Beta-Blockers in Acute Coronary Syndromes   
 
Raffaele Bugiardini, MD a*, Edina Cenko, MD a, Beatrice Ricci, MD a, Zorana 
Vasiljevic, MD, PhD b, Maria Dorobantu, MD, PhD c, Sasko Kedev, MD, PhD d, Marija 
Vavlukis, MD d, Oliver Kalpak, MD d, Paolo Emilio Puddu, MD, PhD e, Olivija 
Gustiene, MD f, Dijana Trininic, MD g, Božidarka Knežević, Md h, Davor Miličić, MD, 
PhD i, Christopher P. Gale MD j , Olivia Manfrini, MD a, Akos Koller, Md, PhD k, Lina 
Badimon, MD, PhD l 
 
Author Affiliation: 
a Department of Experimental, Diagnostic and Specialty Medicine, University of 
Bologna, Bologna, Italy 
b Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia 
c Department of Cardiology and Internal Medicine, Floreasca Emergency Hospital, 
Bucharest, Romania  
d University Clinic of Cardiology, Medical Faculty, University of St.Cyril & Methodius, 
Skopje, Macedonia 
e Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and 
Geriatric Sciences, Sapienza University of Rome, Rome, Italy 
f Department of Cardiology, Lithuanian University of Health Sciences, Kaunas, 
Lithuania 
g Clinical Center of Banja Luka, Banja Luka, Republika Srpska, Bosnia and 
Herzegovina  
h Clinical center of Montenegro, Center of Cardiology, Podgorica, Montenegro 
i Department for Cardiovascular Diseases, University Hospital Center Zagreb, 
University of Zagreb, Zagreb, Croatia 
j Division of Epidemiology and Biostatistics, University of Leeds, Leeds, UK York Teaching 
Hospital NHS Foundation Trust, UK 
k Institute of Natural Sciences, University of Physical  Education, Budapest, H-1123, 
Hungary 
l Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau, 
CiberObn-Institute Carlos III, Autonomous University of Barcelona, Barcelona, Spain 
 
*Corresponding author: Raffaele Bugiardini, MD, FAHA, FACC, FESC. Department 
of Experimental, Diagnostic and Specialty Medicine, University of Bologna. Policlinico 
Sant’Orsola Malpighi, Padiglione 11, Via Massarenti 9 , 40138 Bologna, Italy. 
Telephone and fax number: +39 051347290, e-mail: raffaele.bugiardini@unibo.it 
 
 
 2 
ABSTRACT  
The aim of this study was to determine if earlier administration of oral beta-blocker therapy in 
patients with acute coronary syndromes (ACSs) is associated with increased short-term survival 
and improved left ventricular (LV) function. We studied 11,581 patients enrolled in the 
International Survey of Acute Coronary Syndromes in Transitional Countries ( ISACS-TC) 
registry from January 2010 to June 2014. Of these patients, 6,117 were excluded as they received 
intravenous beta-blockers or remained free of any beta-blocker treatment during hospital stay, 23 
with unknown timing of oral beta-blocker administration was unknown and 182 because they had 
death before oral beta-blockers could be given. The final study population comprised 5,259 
patients. The primary outcome was the incidence of in-hospital mortality. The secondary 
outcome was the incidence of severe LV dysfunction defined as an ejection fraction <40% at 
hospital discharge. Oral beta-blockers were administered soon (≤24 hours) after hospital 
admission in 1,377 patients and later (>24 hours) during hospital stay in the remaining 3,882 
patients. Early beta-blocker therapy was significantly associated with reduced in-hospital 
mortality (odds ratio [OR] 0.41, 95% confidence interval [CI] 0.21 to 0.80) and reduced 
incidence of severe LV dysfunction (OR 0.57, 95% CI 0.42 to 0.78). Significant mortality 
benefits with early beta-blocker therapy disappeared when patients with Killip Class III/IV were 
included as dummy variables. The results were confirmed by propensity score-matched analyses. 
In conclusion, in patients with ACSs, earlier administration of oral beta-blocker therapy should 
be a priority with a higher probability of improving LV function and in-hospital survival. Patients 
presenting with acute pulmonary edema or cardiogenic shock should be excluded from this early 
treatment regimen. 
 
Key Words: Acute Coronary Syndrome; Beta-Blockers; Timing; In-hospital mortality. 
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There is a general consensus that pre-discharge oral beta-blocker therapy leads to improved long-
term clinical outcome in patients with acute coronary syndromes (ACSs) although, within the 
framework of an in-hospital treatment strategy, there is a paucity of data on precisely defining 
when beta-blockers should be started. The most recent practice guidelines from the American 
College of Cardiology (ACC)/American Heart Association (AHA) recommend that oral beta-
blocker therapy should be given in the first 24 hours if patients are at low risk for cardiogenic 
shock [1,2]. Risk of cardiogenic shock, in turn, is based on findings from the COMMIT/CCS-2 
(Chinese Clopidogrel and Metoprolol in Myocardial Infarction Trial) study [3]. American 
recommendation is not reflected by the practice guidelines of the European Society of 
Cardiology (ESC) where decisions on whether to give beta-blocker therapy within 24 hours from 
admission or several days later are left at physicians’ discretion [4,5]. When solid evidence 
exists, guidelines tend to put forward largely overlapping recommendations. Further data are, 
therefore, needed on the relation between outcome and time to beta-blocker treatment in patients 
with ACS. The current study was undertaken to examine the effects of early versus late oral beta-
blocker therapy in patients who had stabilized after an ACS. 
METHODS  
The details of the International Survey of Acute Coronary Syndromes in Transitional 
Countries (ISACS-TC) registry protocol (ClinicalTrials.gov: NCT01218776) have been 
previously published [6,7]. Briefly, the ISACS-TC is both a retrospective -over a one year 
period- and prospective study which was designed in order to obtain data of patients with ACSs, 
and herewith control and optimize internationally guideline recommended therapies in countries 
with economy in transition. Data collection activities began in October 2010 with the aim of 
collecting data on approximately 3000 patients hospitalized with ACS on an annual basis. A total 
of 57 cluster sites in 11 countries in Central and Eastern Europe are currently collaborating in 
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ISACS- TC (Supplemental material). There were 29 tertiary healthcare services providing 
advanced medical investigation and treatment including percutaneous coronary intervention 
(PCI) and/ or cardiac surgery, and 28 secondary healthcare services providing intensive care in 
critical coronary care units.The study was approved by the local research ethics committee from 
each hospital. Patients provided written consent for evaluation of their medical notes and 
monitoring of their health status. 
To avoid survival bias, as patients who were selected for the study would have to survive 
enough to received benefits from medications, a landmark time was used. We defined the 
landmark time as a 24 hours survival interval from beta-blocker administration. The analysis 
then evaluated patients’ outcome from the landmark time through to the end of the follow-up 
period (death or hospital discharge). Patients were also excluded from the analysis if they 
received intravenous beta-blockers or if they remained free of any beta-blocker treatment during 
hospital stay (Figure 1). 
The primary outcome was the incidence of in-hospital mortality. The secondary outcome 
was the incidence of severe left ventricular (LV) dysfunction defined as an ejection fraction by 
echocardiography <40% at hospital discharge. Moreover, to analyze the risk of shock as a 
potential confounder, the COMMIT shock index score was calculated for each patient (0 to 2 
points=low-risk; 3 to 4 point=high-risk) [3]. The shock index includes the following variables: 
age >70 years, symptom onset more than 12 hours, systolic blood pressure (BP) <120 mmHg, 
and heart rate >110 bpm [3]. 
Patients were stratified by time from hospital presentation to beta-blocker treatment 
whether early (24 hours) or delayed (>24 hours to discharge). Baseline characteristics, in-
hospital therapies and clinical outcomes were assessed. Patients were also stratified according to 
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the index event: ST-segment elevation myocardial infarction (STEMI) versus non-ST-segment 
elevation ACS (NSTE-ACS) [8]  and in-hospital management strategies (overall population 
versus only routine medical therapy [RMT]). Standard initial routine medical therapies include 
use of antiplatelet agents with aspirin and P2Y12 inhibitors, and anticoagulation with 
enoxaparin, bivalirudin, fondaparinux, or unfractionated heparin. In addition to standard initial 
antiplatelet/anticoagulant therapy, angiotensin-converting enzyme (ACE) inhibitors and beta-
blockers could be started and continued indefinitely. Statistical testing was performed using a 
Chi-square test for baseline categorical variables and a two sample t-test for continuous variables. 
Estimates of the odds ratio (OR) and associated 95% confidence intervals (CI) were obtained 
using the multivariable logistic regression analysis, adjusting the differences in baseline patient 
characteristics and medications given in the first 24 hours. Constant covariates included in the 
analyses were: 1) sex, 2) age, cardiovascular risk factors: 3) hypercholesterolemia, 4) diabetes, 5) 
hypertension, 6) current smoker, 7) family history of coronary artery disease (CAD), 8) clinical 
history of cardiovascular heart disease (prior angina, prior myocardial infarction, prior coronary 
artery bypass graft and PCI, prior heart failure, peripheral artery disease, prior stroke), 9) chronic 
kidney disease, 10) time from symptom onset to admission < 12 hours and 11) STEMI as index 
event. Covariates introduced as dummy variables were: use of fibrinolysis, aspirin, clopidogrel, 
heparins (unfractioned heparin) ACE inhibitors and Killip class III/ IV. For all analysis, 
statistical significance was defined as a value of p<0.05 and STATA 11 (StataCorp. College 
Station, TX, USA) was used. 
Logistic regression analyses were used to obtain the estimated probabilities P and the 
logits (logit = ln(P/(1-P)), which were considered for the propensity score. The treatment 
variable (early beta-blocker treatment yes/no) was the outcome and the pre-treatment covariates 
were the same 11 predictor variables entered in the above mentioned multivariate models. We, 
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then, assessed early beta-blocker versus delayed treatment effects by NCSS (©) version 9 
routines for data matching (NCSS 9. NCSS, LLC. Kaysville, Utah, USA: www.ncss.com). 
Patients were matched without replacement on a 1:1 basis using a nearest neighbor (Greedy) 
algorithm based on Mahalanobis distance. 
RESULTS 
The baseline characteristics, in-hospital treatments, and outcomes of the overall study 
population (n=5,259) and the RMT sub-group (n=2,601) stratified according to time from 
hospital presentation to beta-blocker administration are listed in Table 1. Average hospital stay 
was 7.8 ± 5.4 days among all patients and 8.2 ± 5.7 days among RMT patients. The 
corresponding values for median stay were respectively 7 and 7 days. Unadjusted in-hospital 
mortality was higher in the RMT group (4.8% versus 3.4%; OR 2.31, 95% CI 1.68 to 3.19, 
p<0.001).  After adjustment RMT was still associated with higher mortality compared with that 
of the overall cohort (OR 1.65, 95% CI 1.08 to 2.51, p=0.02). There were no significant 
differences in the in-hospital rates of death or severe LV dysfunction in patients who underwent 
beta-blocker therapy <6 hours versus those who had such therapy >6 to 24 hours after clinical 
presentation. In contrast, patients who underwent beta-blocker therapy >24 hours after clinical 
presentation had higher rates of death and severe LV dysfunction in comparison with those who 
underwent earlier therapy (Figure 2). The relations between beta-blocker use ≤24 hours and 
subsequent end-points are shown in Table 2. The use of beta-blockers ≤24 hours was 
significantly associated with lower in-hospital mortality and lower incidence of severe LV 
dysfunction in the whole population. A qualitatively similar reduction in risk was seen in the 
RMT subgroup. After multivariable adjustment for demographic and clinical factors, early beta-
blocker treatment remained a strong independent factor associated with better outcomes. STEMI 
patients treated with early beta-blockers had lower rates of adjusted in-hospital mortality and 
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incidence of severe LV dysfunction.  In the NSTE-ACS subgroup the adjusted OR remained 
significantly associated with lower incidence of severe LV dysfunction, but not with decreased 
in-hospital mortality (Figure 3). The adjusted OR associated with early beta-blocker therapy did 
not change when controlling for fibrinolytic, antiplatelet and anticoagulant agents (Table 2). 
Additional analysis revealed that the favorable outcomes associated with early beta-blocker 
treatment disappeared after adjustment for concurrent ACE-inhibitors administration, suggesting 
an interaction between these two compounds. A regression model was, therefore, used to 
evaluate whether the treatment effects of these medications may have interacted. Beta-blockers 
scored significantly for both lower incidence of both in-hospital mortality (OR 0.43, 95% CI 
0.20 to 0.92, p=0.03) and occurrence of severe LV dysfunction at discharge (OR 0.42, 95% CI 
0.29 to 0.62, p<0.001). On the opposite, ACE-inhibitors did not show significant effects either 
on death (OR 0.62, 95% CI 0.29 to 1.32, p=0.21) or severe LV dysfunction (OR 1.44, 95% CI 
0.98 to 2.14, p=0.06). Significant benefits in mortality with early beta-blocker therapy 
disappeared when patients with Killip Class > II were included in the analysis (Table 2), 
indicating that patients with acute pulmonary oedema or cardiogenic shock should be excluded 
from an early beta-blocker treatment regimen. We also investigated the relation between beta-
adrenergic blocker use and clinical correlates of LV function at hospital admission, by using the 
COMMIT-shock index score. We calculated the COMMIT-shock index estimates only for 
patients with Killip class I/II, as for definition patients with Killip Class III/IV have shock or 
high risk for shock (Table 3). In this lower risk population, approximately half (45%) of STEMI 
patients and almost two thirds (65%) of NSTE-ACS patients had two or more risk factors for 
shock. Multivariable regression analysis indicated that all of the individual factors entering the 
shock index were associated with increased in-hospital mortality. However, after adjustment for 
these factors, early beta-blocker use was still significantly associated with better outcomes 
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(Table 3). Delay to beta-blocker therapy >24 hours after clinical presentation was associated 
with significant increases in the rates of severe LV dysfunction among high shock risk score (2 
or more factors) patients (Figure 2). There were very few deaths (n=23) among patients with 
Killip class I/II. Therefore the increased risk of death with delayed beta-blocker therapy was not 
adequately powered to evaluate differences.  Finally, the association between acute beta-blocker 
therapy and in-hospital clinical outcomes also was assessed using propensity score analysis The 
C-statistic for the propensity score logistic regression-based model was 0.70, thus indicating a 
good discriminatory power. Based on this propensity score we matched 927 patients using a  1:1 
model with 11 covariates for early versus delayed treatment (Table 4). The logit propensity 
scores of early versus delayed beta-blocker administration were -0.252 ± 0.704 and -0.240 ± 
0.692, respectively (p=ns). The incidence of the in-hospital mortality was lower in patients with 
early beta-blocker treatment as compared with their delayed treatment counterpart: 1.2% 
(11/927) versus 2.7% (25/927, p=0.018).  
DISCUSSION 
The main findings of this analysis are: (1) delay to oral beta-blocker administration >24 
hours after clinical presentation is a strong, independent predictor of increased in-hospital 
mortality and incidence of severe LV dysfunction across patients presenting in Killip Class I and 
II; (2) the relative risk attributable to beta-blocker administration delay is greatest in STEMI 
patients; (3) benefits of an early administration were independent of an invasive management 
strategy and COMMIT-shock index scores and (4) the results are confirmed by propensity score 
matching. 
The COMMIT trial’s investigators found that while early intravenous beta-blockers 
reduced the risk of death from ventricular fibrillation, and re-infarction, they also can 
significantly increase the risk of cardiogenic shock especially during the first day after admission 
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[3]. In response to the COMMIT results, the ACC/AHA in their updated guidelines on care of 
patients with STEMI [2] acknowledged that some patients are not appropriate for early, 
≤24hours, beta-blocker therapy, namely those patients presenting with high risk for cardiogenic 
shock. Additionally, the guidelines stated that early intravenous beta-blockers should specifically 
be avoided in most patient populations. Despite these recommendations, there seems to be no 
clear consensus among the international cardio-vascular community regarding the appropriate 
time of treatment with beta-blockers in ACS patients. Accordingly, the ESC treatment guidelines 
in this setting are vague. Early beta-blocker treatment is feasible, but guidelines recommend 
waiting for the patient to stabilize before starting therapy. Differences in recommendations stem 
from a paucity of evidence supporting benefits of one strategy over the other on short-term 
outcomes. This may cause some degree of confusion among clinicians and low use of beta-
blockers ≤24 hours in patients who have not relative contraindications [9-13]. The uncertain 
treatment recommendations for these patients are reflected in the different therapeutic strategies 
used in the real life. In the present large-scale, multicenter registry, the vast majority of ACS 
patients eligible to beta-blocker therapy were classified as being with no or moderate signs of 
heart failure, but were prescribed delayed beta-blocker therapy. Only one third (26.2%) of these 
patients received oral beta-blockers within the first 24 hours from hospitalization. Yet, there was 
a strong, independent association, of beta-blocker therapy delay >24 with subsequent in-hospital 
mortality and development of severe LV dysfunction. Clear contraindications to early oral beta-
blocker use may include only severe LV dysfunction, as significant mortality benefits with early 
therapy disappeared when patients with frank acute pulmonary oedema or cardiogenic shock 
were included in the analysis 
The ACC/AHA guidelines recommend that caution should be used when administering 
oral beta-blocker therapy during the first 24 hours of hospital presentation in those patients who 
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have risk factors for shock. These risk factors derived from the COMMIT trial and include age, 
systolic blood pressure, heart rate, and prolonged time from symptom onset to presentation. As 
general beta-blocker contraindications include signs of overt heart failure and evidence of low-
output state, the COMMIT-shock risk factors should represent additional criteria for exclusion 
from early beta-blockers therapy in the remaining patients. We, therefore, examined the effects of 
early oral beta-blocker therapy according to clinical presentation, i.e.  in those patients without 
documented severe heart failure or shock  at admission (Killip Class III/IV). Of note, there was 
no evidence to suggest different outcomes following early beta-blockade in patients having high 
COMMIT-shock index scores, which implies that risk factors for shock do not confer additional 
prognostic information beyond that given by the well established Killip class classification. 
Few studies have examined the care and outcomes of patients with ACS who do not 
receive revascularization therapy [7, 14]. Yet, many of these studies were performed before the 
use of reperfusion therapy with either fibrinolysis or PCI, and mainly focused on beta-blockers 
as part of therapy in the secondary prevention [15-19]. There are no contemporary large studies 
specifically addressing the efficacy of beta-blockers on short-term outcomes in this population. 
We found that early oral beta-blocker use during an ACS significantly preserves left ventricular 
function compared with delayed treatment, thereby suggesting significant myocardial salvage. 
Conversely, the data remains inconclusive regarding the benefit on mortality.  
The present investigation is the largest to date examining the impact of orally 
administered beta-blockers and their treatment-related delays on patient outcomes in ACS 
patients. There are no randomized controlled trials of oral beta-blockers in the setting of ACS 
[12, 20-22]. Other observational studies describing the impact of the timing of beta-blocker 
administration on outcomes of patients with ACS are inconsistent for comparison with our data, 
since these studies are pooled together patients treated both orally and intravenously [23-25]. 
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Furthermore, we created a propensity score for the likelihood [26-28] of undergoing in-hospital 
mortality using multiple logistic regressions with early versus delayed beta-blocker treatment as 
dependent variables and baseline clinical characteristics of the cohort as covariates including the 
index event. The results of the current study were therefore consistent among the two diagnostic 
groups: STEMI and NSTE-ACS 
Our study has some limitations. This study is a post-hoc analysis, and our findings should 
therefore be interpreted as hypothesis-generating. Although the propensity score helps to adjust 
for differences between groups, it does not control for unmeasured differences in clinical care. 
The lack of beta-blocker dosage restricted our ability to assess the dose-dependent effect of 
potential drug interaction. The study excluded 6,322 individuals, as they received intravenous 
beta-blockers or remained free of any beta-blocker treatment during hospital stay. The evidence 
for beta-blocker benefits in post-ACS patient is strong. Conversely, not all studies have 
consistently demonstrated benefit of early intravenous beta-blocker therapy. We therefore 
focused our investigation on the controversial issue on timing of in-hospital oral administration 
rather than on benefits of beta-blocker use whatever the time or the route of administration is. 
Despite these caveats, the present findings, taken in concert with those from earlier studies 
suggest that patients with ACS and low Killip class benefit from urgent oral beta-blocker 
administration given early (≤24 hours). 
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FIGURE LEGENDS:  
Figure 1: Consort flow diagram.  
BB indicates oral beta-blockers; RMT indicates routine medical therapy  
 
Figure 2: Timing of beta blocker administration and outcomes 
BB indicates oral beta-blockers 
 
Figure 3: Effects of early beta-blocker administration on cardiovascular endpoints 
according to the index event. 
Multivariate model adjusted for sex, age, hypercholesterolemia, diabetes mellitus, 
hypertension, current smoker, family history of coronary artery disease, clinical history 
of cardiovascular disease (including prior angina pectoris, prior myocardial infarction, 
prior coronary artery bypass graft and percutaneous coronary intervention, prior heart 
failure, peripheral artery disease and prior stroke), chronic kidney disease and time from 
symptom onset to admission  12 hours 
LV=left ventricular; NSTE-ACS = non-ST-segment elevation acute coronary 
syndromes; STEMI = ST-segment elevation myocardial infarction;  
 
 
 19 
 
Table 1. Baseline Clinical Characteristics 
 Overall population Routine medical therapy  
  
 
 
All 
 
Early Beta 
Blockers 
administratio
n 
 
Delayed Beta 
Blockers 
administratio
n 
 
  
 
 
All 
 
Early Beta 
Blockers 
administratio
n 
 
Delayed Beta 
Blocker 
administratio
n  
  
 
 
p value‡ 
Variable (n=5,259) (n=1,377) (n=3,882) p value* (n=2,601) (n=489) (n=2,112) p value†  
Women 1,681 
(31.9%) 
431 (31.3%) 1,250 (32.2%) 0.53 942 (36.2%) 
188 (38.5%) 
754 (35.7%) 
0.25 <0.001 
Age (years) 62.1 ± 11.9 61.8 ± 11.7 62.2 ± 12.1 0.33 64.0 ± 12.3 65.7 ± 11.7 
63.6 ± 12.4 
<0.001 <0.001 
Hypercholesterolemia 2,010 
(46.8%) 
595 (57.0%) 1,415 (43.5%) <0.001 885 (43.4%) 
162 (58.5%) 
723 (41.0%) 
<0.001 0.01 
Diabetes mellitus 1,256 
(25.0%) 
313 (23.1%) 943 (25.7%) 0.06 680 (27.8%) 
141(29.1%) 
539 (27.5%) 
0.46 0.009 
Hypertension 3,570 
(69.5%) 
993 (75.0%) 2,577 (67.6%) <0.001 
1,768 
(69.8%) 
352 (77.9%) 
1,416 (68.0%) 
<0.001 0.78 
Current smoker 1,790 
(34.6%) 
584 (43.4%) 1,206 (31.5%) <0.001 744 (29.2%) 
174 (36.6%) 
570 (27.5%) 
<0.001 <0.001 
Former smoker 408 (7.9%) 157 (11.7%) 251 (6.6%) <0.001 218 (8.6%) 
49 (10.3%) 
169 (8.2%) 
0.12 0.28 
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Family history of CAD 2,032 
(41.8%) 
378 (29.8%) 1,654 (46.0%) <0.001 878 (36.4%) 
103 (23.5%) 
775 (39.2%) 
<0.001 <0.001 
Prior angina pectoris 1,361 
(25.9%) 
495 (35.9%) 866 (22.3%) <0.001 721 (27.7%) 
225 (46.0%) 
496 (23.5%) 
<0.001 0.08 
Peripheral artery disease 165 (3.1%) 24 (1.7%) 141 (3.6%) 0.001 106 (4.1%) 
12 (2.5%) 
94 (4.5%) 
0.04 0.02 
Prior myocardial infarction 921 (17.5%) 185 (13.4%) 736 (18.9%) <0.001 544 (20.9%) 
96 (19.6%) 
448 (21.2%) 
0.43 <0.001 
Prior coronary artery bypass 
graft  
156 (3.0%) 27 (1.9%) 129 (3.2%) 0.01 104 (4.0%) 
17 (3.5%) 
87 (4.1%) 
0.51 0.009 
Prior percutaneous coronary 
intervention  
989 (18.8%) 86 (6.3%) 903 (23.3%) <0.001 330 (12.7%) 
34 (6.9%) 
296 (14.0%) 
<0.001 <0.001 
Prior heart failure 263 (5.0%) 160 (11.6%) 103 (2.7%) <0.001 159 (6.1%) 
75 (15.3%) 
84 (4.0%) 
<0.001 0.04 
Prior stroke 268 (5.1%) 53 (3.8%) 215 (5.5%) 0.01 163 (6.3%) 
30 (6.1%) 
133 (6.3%) 
0.89 0.03 
Chronic kidney disease 278 (5.3%) 75 (5.5%) 203 (5.3%) 0.80 180 (7.0%) 
42 (8.6%) 
138 (6.6%) 
0.11 <0.001 
Killip class I and II 4,840 
(92.0%) 
1,324 (96.2%) 3,516 (90.6%) <0.001 
2,294 
(88.2%) 
453 (92.6%) 
1,841 (87.2%) 
0.001 <0.001 
Time from symptom onset to 
admission  12 hours 
3,420 
(70.3%) 
994 (74.1%) 2,426 (68.8%) <0.001 
1,488 
(61.9%) 
308 (66.2%) 
1,180 (60.9%) 
0.03 <0.001 
Serum Creatinine  (µmol/L) 95.5 ± 73.5 92.2 ± 61.7 104.2 ± 97.4 0.002 10.6 ± 86.3 
99.1 ± 54.7 
112.9 ± 118.6 
0.02 
0.006 
Heart rate (beats/min)  82.3 ± 25.5 82.9 ± 22.8 81.9 ± 27.5 0.28 83.9 ± 24.9 
87.4 ± 30.9 
82.4 ± 21.8 
<0.001 0.05 
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Systolic blood pressure  
(mmHg)  
140.5 ± 26.9 143.6 ± 25.3 137.9 ± 28.0 <0.001 140.3 ± 27.7 
144.1 ± 25.3 
138.7 ± 28.4 
<0.001 0.71 
Index event         
STEMI 3,742 
(71.2%) 
846 (61.4%) 2,896 (74.6%) <0.001 
1,595 
(61.3%) 
202(41.3%) 1,393 (65.9%) <0.001 <0.001 
NSTE-ACS 1,517 
(28.8%) 
531 (38.6%) 986 (25.4%) <0.001 
1,006 
(38.7%) 
287 (58.7%) 719 (34.0%) <0.001 <0.001 
In-hospital acute medications (within 24 hours)       
Fibrinolytic therapy 767 (14.6%) 122 (8.9) % 645 (16.7%) <0.001 557 (21.5%) 85 (17.4%) 472 (22.4%) 0.01 <0.001 
Aspirin 5,126 
(97.8%) 
1,363 
(99.1%) 
3,763 (97.3%) <0.001 
2,498 
(96.3%) 
479 (98.2%) 2,019 (95.8%) 0.01 <0.001 
Clopidogrel 4642 
(88.9%) 
1,321 
(96.2%) 
3,321 (86.3%) <0.001 
2,060 
(79.7%) 
450 (92.6%) 1,610 (76.7%) <0.001 <0.001 
Unfractioned heparins 2379 
(46.1%) 
729 (53.1%) 1,650 (43.5%) <0.001 935 (36.8%) 12 0 (24.6%) 815 (39.7%) <0.001 <0.001 
Low molecular weight 
heparins  
1857 
(41.9%) 
880 (64.2%) 977 (31.9%) <0.001 
1,131 
(49.9%) 
403 (82.8%) 728 (40.9%) <0.001 <0.001 
Fondaparinux 70 (1.6%) 19 (1.4%) 51 (1.7%) 0.48 46 (2.0%) 3 (0.6%) 43 (2.4%) 0.01 0.23 
Glycoprotein  IIb/IIIa 
inhibitors 
225 (7.4%) 87 (6.4%) 138 (8.2%) 0.05 20 (1.2%) 1 (0.2%) 19 (1.6%) 0.01 <0.001 
Beta-blockers 1377 
(26.2%) 
1,377 
(100%) 
- - 489 (18.8%) 489 (100.0%) - - <0.001 
ACE inhibitor 1244 
(27.7%) 
1,156 
(95.2%) 
88 (2.7%) <0.001 432 (19.6%) 404 (96.4%) 28 (1.6%) <0.001 <0.001 
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In-hospital procedures       
Coronary angiography 2866 
(55.7%) 
994 (75.7%) 1,872 (48.9%) <0.001 266 (10.5%) 115 (26.6%) 151 (7.2%) <0.001 <0.001 
Percutaneous coronary 
intervention  
2585 
(49.3%) 
878 (64.2%) 1,707 (44.7%) <0.001 - - - - - 
Coronary artery bypass graft  21 (0.4%) 7 (0.5%) 14 (0.4%) 0.45 - - - - - 
Outcomes           
In-hospital mortality 179 (3.4%) 25 (1.8%) 154 (4.0%) <0.001 124 (4.8%) 17 (3.5%) 107 (5.1%) 0.13 0.002 
Severe LV dysfunction 546 (24.4%) 237 (20.3%) 309 (28.9%) <0.001 323 (27.8%) 104 (24.2%) 219 (29.8%) 0.04 0.03 
Data expressed as mean ± SD or as number (percentage). 
* p value derived from comparison between Early versus Delayed beta-blockers administration in the overall population 
†p value derived from comparison between Early versus Delayed beta-blockers administration in the Routine medical therapy subgroup 
‡p value derived from comparison between beta-blockers administration in the overall population versus Routine medical therapy subgroup 
 ACE = angiotensin converting enzyme; CAD = coronary artery disease; LV = left ventricular; NSTE-ACS = non-ST-segment elevation acute coronary 
syndromes 
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Table 2. Adjusted In-Hospital Outcomes in Acute Coronary Syndrome Patients Treated with Early Beta-blocker Administration  
 Overall population Routine medical therapy  
 N OR 95% CI p value N OR 95% CI p value 
Multivariate adjusted models:  
Model 1: Demographic and clinical factors* 
In-hospital mortality 3,557 0.41 0.21 - 0.80 0.01 1,681 0.75 0.29 - 1.92 0.56 
Severe LV dysfunction 1,421 0.57 0.42 - 0.78 <0.001 659 0.37 0.20 - 0.67 0.001 
Model 2: Model 1 including Fibrinolysis 
In-hospital mortality 3,544 0.39 0.20 - 0.77 0.007 1,676 0.74 0.29 - 1.88 0.52 
Severe LV dysfunction 1,418 0.55 0.40 - 0.75 <0.001 659 0.37 0.20 - 0.66 0.001 
Model 3: Model 1 including Fibrinolysis and Aspirin 
In-hospital mortality 3,535 0.40 0.20 - 0.78 0.008 1,673 0.76 0.30 - 1.94 0.57 
Severe LV dysfunction 1,415 0.55 0.40 - 0.75 <0.001 657 0.35 0.19 - 0.64 0.001 
Model 4: Model 1 including Fibrinolysis, Aspirin and/or Clopidogrel 
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In-hospital mortality 3,544 0.41 0.21 - 0.80 0.01 1,676 0.77 0.30 - 1.94 0.58 
Severe LV dysfunction 1,418 0.56 0.41 - 0.76 <0.001 659 0.37 0.21 - 0.67 0.001 
Model 5: Model 1 including Fibrinolysis, Aspirin and/or Clopidogrel, and Unfractioned heparin  
In- hospital mortality 3,496 0.37 0.19 - 0.73 0.004 1,638 0.77 0.30-1.98 0.60 
Severe LV dysfunction 1,397 0.54 0.39 - 0.75 <0.001 642 0.34 0.18 -0.63 0.001 
Model 6: Model 1 including Fibrinolysis, Aspirin and/or Clopidogrel, Unfractioned heparin and ACE-Inhibitors 
In-hospital mortality 1,308 0.57 0.19 - 1.71 0.32 447 1.97 0.47 - 8.22 0.35 
Severe LV dysfunction 848 0.59 0.34 - 1.02 0.06 267 0.28 0.11 - 0.74 0.01 
Model 7: Model 1 including Killip class III/ IV 
In-hospital mortality 
3,557 0.53 0.27 - 1.04 0.06 1,681 0.93 0.36 - 2.38 0.88 
Severe LV dysfunction 
1,421 0.68 0.50 - 0.92 0.01 659 0.46 0.24 - 0.83 0.01 
*Demographic and clinical factors: sex, age, hypercholesterolemia, diabetes mellitus, hypertension, current smoker, family history of CAD, 
clinical history of cardiovascular disease (including prior angina pectoris, prior myocardial infarction, prior coronary artery bypass graft and 
percutaneous coronary intervention , prior heart failure, peripheral artery disease and prior stroke), chronic kidney disease, time from symptom 
onset to admission  12 hours and STEMI as index event. 
ACE = angiotensin-converting-enzyme; CAD = coronary artery disease; LV= left ventricular; STEMI = ST-segment elevation myocardial 
infarction 
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Table 3. Associations Among In-Hospital Outcomes, Timing Of Beta-Blockers Administration and COMMIT-Shock Index  
 Overall population Routine medical therapy 
 OR 95% CI p value OR 95% CI p value 
In hospital mortality 
 N=2,991 N=1,656 
Beta blockers administration ≤ 24 hours 0.51 0.32 - 0.84 0.008 0.70 0.39 - 1.25 0.23 
Age > 70 years 3.08 1.99 - 4.75 <0.001 2.34 1.44 - 3.81 0.001 
Time from symptom onset to admission > 12 hours 1.82 1.18 - 2.82 0.007 1.79 1.10 - 2.91 0.01 
Systolic blood pressure < 120 mmHg 2.09 1.29 - 3.39 0.003 2.27 1.33 - 3.86 0.003 
Heart rate >110 beats/min 2.66 1.45 - 4.89 0.002 2.13 1.10-4.15 0.02 
Severe LV dysfunction  
 N=2,183 N=1,130 
Beta blockers administration ≤ 24 hours 0.64 0.52 - 0.78 <0.001 0.72 0.54 - 0.96 0.02 
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Age > 70 years 1.51 1.22 - 1.87 <0.001 1.23 0.94 - 1.62 0.12 
Time from symptom onset to admission > 12 hours 1.07 0.86 - 1.34 0.49 1.27 0.96 - 1.67 0.09 
Systolic blood pressure < 120 mmHg 1.25 0.96 - 1.64 0.09 1.10 0.77 - 1.58 0.59 
Heart rate  >110 beats/min 2.30 1.58 - 3.36 <0.001 2.25 1.44 - 3.50 <0.001 
COMMIT= Chinese Clopidogrel and Metoprolol in Myocardial Infarction Trial; LV= left ventricular 
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Table 4. Propensity score matching: Early versus Delayed Beta-Blocker Administration 
 Early Beta 
Blockers 
administration 
N=927 
Delayed Beta 
Blockers 
administration 
N=927 
p 
value 
Logit propensity score (Ln(PS/(1-PS))), 
mean ± SD 
-0.252±0.704 
 
-0.240±0.692 
 
0.99 
Women  292 (31.5%) 305 (32.9%) 0.52 
Age (years) 61.1 ± 11.7 61.3 ± 11.9 0.69 
Hypercholesterolemia 519 (55.9%) 512 (55.2%) 0.74 
Diabetes mellitus 190 (20.5%) 195 (21.0%) 0.77 
Hypertension 694 (74.9%) 693 (74.8%) 0.96 
Current smoker 400 (43.1%) 404 (43.6%) 0.85 
Family history of CAD 304 (32.8%) 310 (33.4%) 0.77 
Clinical history of cardiovascular disease* 421(45.4%) 400 (43.1%) 0.33 
Chronic kidney disease 48 (5.2%) 43 (4.6%) 0.59 
Time from symptom onset to admission  
12 hours 
715 (77.1%) 740 (79.8%) 0.16 
STEMI 585 (63.1%) 608 (65.6%) 0.26 
Primary Outcome  
In-hospital mortality 11 (1.2%) 25 (2.7%) 0.018 
Odds ratio (95%Confidence Intervals) 0.43 (0.21 - 0.89) 0.022 
Data expressed as mean ± SD or as number (percentage).  
CAD = coronary artery disease; PS = propensity score; STEMI = ST-segment elevation 
myocardial infarction 
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*Clinical history of cardiovascular disease including prior angina pectoris, prior myocardial 
infarction, prior coronary artery bypass graft and/or prior percutaneous coronary 
intervention, prior heart failure, peripheral artery disease and prior stroke. 
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